Verrica Pharmaceuticals Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| VERRICA PHARMACEUTICALS INC. | ||
| By: | /s/ Jayson Rieger | |
| March 11, 2026 | Jayson RiegerPresident and Chief Executive Officer |
|---|
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jayson Rieger and John J. Kirby, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Verrica Pharmaceuticals Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Jayson Rieger | President, Chief Executive Officer and Director (Principal Executive Officer) | March 11, 2026 |
| Jayson Rieger | ||
| /s/ John J. Kirby | Interim Chief Financial Officer(Interim Principal Financial Officer and Interim Principal Accounting Officer) | March 11, 2026 |
| John J. Kirby | ||
| /s/ Paul B. Manning | Chairman of the Board of Directors | March 11, 2026 |
| Paul B. Manning | ||
| /s/ Gavin Corcoran | Director | March 11, 2026 |
| Gavin Corcoran | ||
| /s/ Lawrence Eichenfield | Director | March 11, 2026 |
| Lawrence Eichenfield | ||
| /s/ Charles Frantzeb | Director | March 11, 2026 |
| Charles Frantzeb | ||
| /s/ Diem Nguyen | Director | March 11, 2026 |
| Diem Nguyen | ||
| /s/ Mark Prygocki | Director | March 11, 2026 |
| Mark Prygocki | ||
| /s/ Sean Stalfort | Director | March 11, 2026 |
| Sean Stalfort | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.